STATEMENT: PRA on the Biden Administration Changing Course on Enforcement of Drug Price Disclosure Provision

Today, PatientRightsAdvocate.org Founder and Chairman Cynthia Fisher released the following statement on the Centers for Medicare and Medicaid Services (CMS) announcing enforcement of the transparency in coverage (TiC) rule covering the disclosure of the cost of prescription drugs:

“We are pleased to hear CMS is changing course and will begin enforcing the drug price disclosure provisions of the Transparency in Coverage rule. For too long, patients, employers, and unions have been left in the dark about the true cost of their healthcare, including prescription drugs. Now, consumers will be empowered to take control of their healthcare spend, lower their costs, and put those savings into employee wages. We encourage Congress to continue diligently working to codify and strengthen hospital and insurer price transparency rules to protect all American consumers.”

Previous
Previous

New PRA Report: Healthcare Price Transparency Can Reduce Healthcare Costs by More than $1 Trillion Annually

Next
Next

PRA Submits Comments on the 2024 OPPS Rule